CN1087778C - 杂交瘤细胞无血清培养基 - Google Patents
杂交瘤细胞无血清培养基 Download PDFInfo
- Publication number
- CN1087778C CN1087778C CN99113498A CN99113498A CN1087778C CN 1087778 C CN1087778 C CN 1087778C CN 99113498 A CN99113498 A CN 99113498A CN 99113498 A CN99113498 A CN 99113498A CN 1087778 C CN1087778 C CN 1087778C
- Authority
- CN
- China
- Prior art keywords
- serum
- medium
- culture medium
- hybridoma cells
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 6
- 210000002966 serum Anatomy 0.000 title abstract description 12
- 210000004881 tumor cell Anatomy 0.000 title 1
- 239000002609 medium Substances 0.000 claims abstract description 23
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 18
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 14
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000012980 RPMI-1640 medium Substances 0.000 claims abstract description 7
- 102000004338 Transferrin Human genes 0.000 claims abstract description 7
- 108090000901 Transferrin Proteins 0.000 claims abstract description 7
- 239000012581 transferrin Substances 0.000 claims abstract description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims abstract description 5
- 239000004017 serum-free culture medium Substances 0.000 claims abstract description 5
- 239000011734 sodium Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- FBKIASNRVHFWNA-USHJOAKVSA-N O.O.[Na].[Na].N[C@@H](Cc1ccc(O)cc1)C(O)=O Chemical compound O.O.[Na].[Na].N[C@@H](Cc1ccc(O)cc1)C(O)=O FBKIASNRVHFWNA-USHJOAKVSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 2
- 229910018590 Ni(NO3)2-6H2O Inorganic materials 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229940054269 sodium pyruvate Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 25
- 239000012679 serum free medium Substances 0.000 abstract description 11
- 239000011573 trace mineral Substances 0.000 abstract description 5
- 235000013619 trace mineral Nutrition 0.000 abstract description 5
- 229940088594 vitamin Drugs 0.000 abstract description 5
- 229930003231 vitamin Natural products 0.000 abstract description 5
- 235000013343 vitamin Nutrition 0.000 abstract description 5
- 239000011782 vitamin Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000016784 immunoglobulin production Effects 0.000 abstract description 2
- 239000003270 steroid hormone Substances 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- -1 iron ions Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3as,4s,6ar)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FICJPXBVKRHEDD-UHFFFAOYSA-N C(C(O)C)(=O)O.[S] Chemical compound C(C(O)C)(=O)O.[S] FICJPXBVKRHEDD-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108010001103 Glutathione oxidase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明属于生物技术领域,公开了一种杂交瘤细胞无血清培养基。所说的培养基是以培养基RPMI 1640为基础,添加了转铁蛋白、甾体激素、微量元素、维生素、乙醇胺、β-巯基乙醇和对羟基苯甲酸等物质所组成的一种新的能使杂交瘤细胞可以旺盛地生长、细胞密度和单抗生产可与有血清培养基相媲美的低蛋白无血清培养基,完全可以替代有血清的培养基用于WuT3杂交瘤细胞的培养。
Description
本发明涉及一种细胞培养基,尤其涉及一种杂交瘤细胞培养基。
杂交瘤细胞是一种能分泌单一独特抗体的无限传代细胞。杂交瘤细胞技术首先由英国的Kohler和Mistein在1975年通过小鼠骨髓瘤细胞和小鼠脾细胞融合而建立的。杂交瘤细胞所分泌的单克隆抗体在诊断、免疫、纯化、疫苗生产、治疗和基础研究等方面有着广泛的应用,已成为生物工程方面的重要产品。
杂交瘤细胞的培养通常是在有血清培养基中进行的,虽然细胞密度和产物的浓度均较高,但由于血清中蛋白和其它大分子物质太复杂,影响了单克隆抗体的分离和纯化,使单克隆抗体的收率和纯度降低,限制了单克隆抗体的体内应用;同时,由于血清的添加也使生产成本大大提高。因此,许多科研工作者致力于开发无血清或低血清培养基。
Darfler等开发的CITTL无血清培养基以DMEM/F12(1∶1)为基础培养基,添加了5mg/L的过氧化氢酶,1.5mg/L的胰岛素,1.5~3.0mg/L转铁蛋白,2nmol/L睾酮,0.5mg/L的二亚油酰磷脂胆碱和1.5mg/L的β-甘油磷酸。这一培养基可支持s49细胞的克隆化生长,也可用于杂交瘤细胞的培养;
文献“Chang TH,Steplewski Z and Koprowski H.Production of Mab in SFM.J.Immunol.Methods.1980,39:369”所报导的无血清培养基成功地培养了几株杂交瘤细胞,其基本培养基是MEM或RPMI 1640,并添加了0.6mg/L的谷氨酰胺,1%MEM的非必需氨基酸,5mg/L的胰岛素和5mg/L转铁蛋白;
Murakami等开发的无血清培养基以DMEM/F12为基础,添加了5mg/L的胰岛素,2~35mg/L转铁蛋白,20μmol/L乙醇胺和1nmol/L亚硒酸钠等物质,这就是现在被广泛使用的DMEM/F12-ITES配方,可培养多种杂交瘤细胞。
Kover和Frank开发的无血清培养基以RPMI 1640为基础培养基,并添加了10mg/L胰岛素,5mg/L转铁蛋白,20μmol/L乙醇胺,5mg/L亚油酸,1g/L牛血清蛋白,3mg/L抗坏血酸,2μg/L氢化可的松和12种微量元素,这一培养基也可使多种骨髓瘤细胞和杂交瘤细胞得以生长。
美国专利U.S.P.4927762公开了一种含有抗氧化剂的培养基,阐明了细胞在还原性介质中能更好地生长,同时指出了N-乙酰半胱氨酸、硫乳酸、巯基乙醇等物质的添加可以起到抗氧化作用。
美国专利U.S.P.4767704公开的培养基就微量元素的添加进行了研究,开发了一种无蛋白培养基,该专利最主要的贡献在于使人们认识到微量元素的作用。
上述的培养基都具有各自的特点,但是各个培养基均只适合于一种或一类细胞的生长,而且蛋白含量仍较高,一般可达每升几十毫克至几克,不利于产物的分离纯化,生产成本也较高。
为了满足人们的需要,研究开发新的低蛋白无血清培养基将是很有意义的。
本发明的目的在于公开一种低蛋白无血清培养基,用于培养鼠-鼠杂交细胞瘤,特别是由骨髓瘤细胞NSl和经免疫的Balb/c小鼠脾细胞融合而成的WuT3杂交瘤细胞,分泌抗人T淋巴细胞CD3抗原的单克隆抗体,该培养基具有蛋白含量低,分离纯化容易,易于工业化生产的特点。
本发明的构思是:一个培养基,除了无机盐、糖、氨基酸和维生素外,还需添加结合蛋白、激素、生长因子、低分子量营养物质等,故本发明在配方中加入了:
(1)转铁蛋白,结合铁的糖蛋白,与细胞表面专一受体作用,传递铁离子,协助铁的吸收,可络合有害离子,起解毒作用,同时还有生长因子的作用。
(2)甾体激素,如地塞米松,对细胞的生理代谢有复杂的调节作用
(3)微量元素,如Cu、Fe、Zn、Se、Co、Mo、Sn、Si等,主要起细胞生理过程调节和控制作用,例如:
Fe:酶和血红素的辅基,是线粒体中呼吸链的组成部分。
Cu:超氧化物歧化酶的辅基。
Mg:对ATP酶、激酶等起活化作用。
Zn:酶的辅基。
Co:B12的组成部分。
Se:是谷胱甘肽氧化酶的组成部分,具有抗氧化作用。
(4)维生素:在细胞生长代谢过程中,维生素不作为能源,它是细胞组成成分,细胞的各种代谢活动,离开了维生素都无法进行,因此它是必需的。
(5)乙醇胺:是无血清培养基的重要组成部分,与磷脂的合成有关。
(6)β-巯基乙醇:促进胱氨酸的吸收,还可使谷胱甘肽处于还原状态,从而保护免受过氧化氢的损害。
(7)对羟基苯甲酸:是氨基酸和糖代谢的中间体,有利于细胞生长代谢。
此外,脂肪酸等对细胞的生长均有一定的促进作用,因此,本发明在培养基RPMI 1640的基础上添加了上述物质,使杂交瘤细胞可以旺盛地生长,细胞密度和单抗生产可与有血清培养基相媲美。
本发明所说的培养基为一个组合物,是由培养基RPMI 1640和下例添加物所组成,添加量均为mg/L:L-精氨酸 100~300 CuSO4·5H2O 0.0005~0.005L-天门冬酰胺 25~75 MnCl2·4H2O 0.00005~0.0005L-天门冬氨酸 10~30 Na2MoO4·2H2O 0.00002~0.0002L-谷氨酸 10~30 Ni(NO3)2·6H2O 0.00002~0.0002L-谷氨酰胺 0~500 ZnSO4·7H2O 0.06~0.6甘氨酸 5~15 CoCl2·6H2O 0.001~0.008L-组氨酸 10~30 NaSiO3·9H2O 0.001~0.01L-异亮氨酸 25~75 Na3VO4·12H2O 0.0005~0.005L-赖氨酸盐酸 20~60 SnCl2·2H2O 0.00001~0.0001L-蛋氨酸 10~30 Na2SeO3 0.002~0.01L-苯丙氨酸 10~30 FeSO4·7H2O 0.2~1.6L-脯氨酸 10~30 葡萄糖 1000~4000L-丝氨酸 15~45 维生素C 0.176~0.704L-苏氨酸 10~30 对羟基苯甲酸 0.5~1.5L-色氨酸 5~15 丙酮酸钠 55~550L-缬氨酸 10~30 亚油酸 0.01~0.05L-亮氨酸 25~75 β-巯基乙醇 0.8~4.0二水L-酪氨酸二钠 144~432 乙醇胺 1~5L-胱氨酸二盐酸 25~75 地塞米松 0.001~0.005人转铁蛋白 5~50
以下将通过实施例对本发明的有关内容作进一步的说明。
实施例1
在500ml细胞培养瓶中,加入20ml如下所示的培养基,然后再加入在该培养基中适应的WuT3杂交瘤细胞,接种密度为1.5×105cells/ml,培养时间为4天,细胞密度(▲)最大为1.5×106cells/ml,单抗浓度(Δ)为65mg/L。L-精氨酸 400 Ca(NO3)·4H2O 100L-天门冬酰胺 100 CoCl2·6H2O 0.00238L-天门冬氨酸 40 CuSO4·5H2O 0.0025L-胱氨酸二盐酸 100 FeSO4·7H2O 0.834L-谷氨酸 40 KCl 400L-谷氨酰胺 600 MgSO4 48.84L-组氨酸 30 MnCl2·4H2O 0.0001甘氨酸 20 Na2HPO4 800L-异亮氨酸 100 Na2MoO4·2H2O 0.00012L-亮氨酸 100 Na2SeO3 0.00864L-赖氨酸盐酸 80 Na3VO4·12H2O 0.001L-蛋氨酸 30 NaCl 6000L-苯丙氨酸 30 NaHCO3 2000L-脯氨酸 40 NaSiO3·9H2O 0.0522L-丝氨酸 60 Ni(NO3)2·6H2O 0.00007L-苏氨酸 40 SnCl2·2H2O 0.000056L-色氨酸 10 ZnSO4·7H2O 0.2875二水L-酪氨酸二钠576 地塞米松 0.002L-缬氨酸 40 葡萄糖 4000β-巯基乙醇 1.58 乙醇胺 3人转铁蛋白 10 还原型谷胱甘肽 1.0亚油酸 0.028 丙酮酸钠 110酚红 5.0 对羟基苯甲酸 1.0维生素C 0.352 生物素(Biotin) 0.20泛酸钙 0.25 氯化胆碱 3.0叶酸 1.0 肌醇 35.0烟酰胺 1.0 对氨基苯甲酸 1.0盐酸吡哆醇 1.0 核黄素 0.20硫胺素 1.0 维生素B12 0.005
对比例
采用与实施例1相同的培养方法,所用的培养基为添加了5%(wt%)血清的RPMI 1640,其细胞密度(■)最大为1.1×106cells/ml,单抗浓度(□)为52mg/l。
由上述实施例和对比例可见,本发明所说的培养基无论在细胞密度和单抗浓度上都优于有血清的培养基,因此完全可以替代有血清的培养基用于WuT3杂交瘤细胞的培养。图1为
本发明所说的无血清培养基还可以用于其它鼠-鼠杂交瘤细胞的培养,是一种低蛋白、低成本的无血清培养基。
Claims (1)
1.一种杂交瘤细胞无血清培育基,其特征在于所说的培养基为一个组合物,是由培养基RPMI 1640和下例添加物所组成,添加量均为mg/L:L-精氨酸 100~300 CuSO4·5H2O 0.0005~0.005L-天门冬酰胺 25~75 MnCl2·4H2O 0.00005~0.0005L-天门冬氨酸 10~30 Na2MoO4·2H2O 0.00002~0.0002L-谷氨酸 10~30 Ni(NO3)2·6H2O 0.00002~0.0002L-谷氨酰胺 0~500 ZnSO4·7H2O 0.06~0.6甘氨酸 5~15 CoCl2·6H2O 0.001~0.008L-组氨酸 10~30 NaSiO3·9H2O 0.001~0.01L-异亮氨酸 25~75 Na3VO4·12H2O 0.0005~0.005L-赖氨酸盐酸 20~60 SnCl2·2H2O 0.00001~0.0001L-蛋氨酸 10~30 Na2SeO3 0.002~0.01L-苯丙氨酸 10~30 FeSO4·7H2O 0.2~1.6L-脯氨酸 10~30 葡萄糖 1000~4000L-丝氨酸 15~45 维生素C 0.176~0.704L-苏氨酸 10~30 对羟基苯甲酸 0.5~1.5L-色氨酸 5~15 丙酮酸钠 55~550L-缬氨酸 10~30 亚油酸 0.01~0.05L-亮氨酸 25~75 β-巯基乙醇 0.8~4.0二水L-酪氨酸二钠144~432 乙醇胺 1~5L-胱氨酸二盐酸25~75 地塞米松 0.001~0.005人转铁蛋白 5~50。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99113498A CN1087778C (zh) | 1999-03-02 | 1999-03-02 | 杂交瘤细胞无血清培养基 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99113498A CN1087778C (zh) | 1999-03-02 | 1999-03-02 | 杂交瘤细胞无血清培养基 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1229851A CN1229851A (zh) | 1999-09-29 |
CN1087778C true CN1087778C (zh) | 2002-07-17 |
Family
ID=5276681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99113498A Expired - Fee Related CN1087778C (zh) | 1999-03-02 | 1999-03-02 | 杂交瘤细胞无血清培养基 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1087778C (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100364527C (zh) * | 2003-07-23 | 2008-01-30 | 华晨 | 一种维生素c与精氨酸的组合物及其应用 |
CN101508976B (zh) * | 2009-01-16 | 2011-04-20 | 吉林大学 | 一种制备单克隆抗体的杂交瘤细胞克隆用培养基及制备方法 |
CN103012590B (zh) * | 2012-09-19 | 2014-06-11 | 上海瀚康生物医药科技有限公司 | 一种抗cd20单克隆抗体及其制备方法和用途 |
CN102994441A (zh) * | 2012-09-19 | 2013-03-27 | 上海瀚康生物医药科技有限公司 | 一种细胞培养基及其制备方法和用途 |
CN104087558A (zh) * | 2014-07-08 | 2014-10-08 | 西藏天虹科技股份有限责任公司 | 一种杂交瘤细胞无血清培养基 |
CN104099392B (zh) * | 2014-07-08 | 2017-01-25 | 苏州康聚生物科技有限公司 | 高糖基化修饰的重组人红细胞生长刺激蛋白的工业化生产方法 |
CN107022528A (zh) * | 2017-05-18 | 2017-08-08 | 武汉博士德生物工程有限公司 | 一种用于培养杂交瘤细胞的培养基及其应用 |
CN107099508A (zh) * | 2017-06-23 | 2017-08-29 | 曲宝赤 | 一种无血清杂交瘤细胞培养基 |
CN107047542B (zh) * | 2017-06-23 | 2020-09-01 | 友康恒业生物科技(北京)有限公司 | 一种无血清细胞冻存液 |
CN110117573A (zh) * | 2019-04-15 | 2019-08-13 | 河北省科学院生物研究所 | 一种无血清细胞培养基及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088984A (zh) * | 1993-11-11 | 1994-07-06 | 江西省医学科学研究所 | 一种用于造血祖细胞培养的无血清培养基 |
CN1205737A (zh) * | 1995-12-21 | 1999-01-20 | 雀巢制品公司 | 改良无限增殖化人类皮肤细胞系和用于其生产的新型无血清培育基 |
-
1999
- 1999-03-02 CN CN99113498A patent/CN1087778C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088984A (zh) * | 1993-11-11 | 1994-07-06 | 江西省医学科学研究所 | 一种用于造血祖细胞培养的无血清培养基 |
CN1205737A (zh) * | 1995-12-21 | 1999-01-20 | 雀巢制品公司 | 改良无限增殖化人类皮肤细胞系和用于其生产的新型无血清培育基 |
Also Published As
Publication number | Publication date |
---|---|
CN1229851A (zh) | 1999-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101603026B (zh) | 适于动物细胞产品生产的无动物来源低蛋白培养基 | |
US4767704A (en) | Protein-free culture medium | |
US5232848A (en) | Basal nutrient medium for cell culture | |
US20150329830A1 (en) | Myeloma cell culture in transferrin-free low iron medium | |
US4816401A (en) | Serum free cell culture medium | |
CN100362098C (zh) | 适用于多种动物细胞大规模培养的无血清培养基 | |
CN102827804B (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
CN101418330B (zh) | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 | |
CN1087778C (zh) | 杂交瘤细胞无血清培养基 | |
JP2001505058A (ja) | 無血清細胞培養培地 | |
JPH06511389A (ja) | 動物細胞培養 | |
WO2006047380A2 (en) | Method and media for single cell serum-fee culture of cho cells | |
CN102317440A (zh) | 改进的培养基添加剂及其应用方法 | |
CN106834229A (zh) | 用于人免疫杀伤细胞体外扩增的无血清培养基 | |
CN111996161A (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN104328158B (zh) | 适于动物细胞表达产品大规模生产的化学成分明确培养基 | |
CN102021139A (zh) | 一种中国仓鼠卵巢细胞培养基及其制备方法和应用 | |
EP0659880B1 (en) | Medium for culturing animal cells or antibody-producing cells | |
CN106399224A (zh) | 无血清无蛋白细胞培养基 | |
CA2111984A1 (en) | Iron chelate culture medium additive | |
CN101319200A (zh) | 一种适用于微囊化cho细胞的无血清培养基及其应用 | |
CN1362514A (zh) | 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 | |
Ducommun et al. | The role of vitamins and amino acids on hybridoma growth and monoclonal antibody production | |
CN118325843A (zh) | 适于杂交瘤细胞悬浮培养和单克隆抗体生产的低蛋白无血清培养基及其应用 | |
EP1651754B1 (en) | Myeloma cell culture in transferrin-free low iron medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |